Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study
Clinical Infectious Diseases · 26.07.2023 · 77 (2) · 194-202
DOI: 10.1093/cid/ciad143 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 11.03.2023. Verfasst von Christian R Kahlert und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St. Gallen, Switzerland. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swiss National Sciences Foundation.
Abstract (Originalsprache)
Background
Disentangling the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and vaccination on the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and reduce the burden of PASC.
Methods
We performed a cross-sectional analysis (May/June 2022) within a prospective multicenter healthcare worker (HCW) cohort in north-eastern Switzerland. HCWs were stratified by viral variant and vaccination status at time of their first positive SARS-CoV-2 nasopharyngeal swab. HCWs without positive swab and with negative serology served as controls. The sum of 18 self-reported PASC symptoms was modeled with univariable and multivariable negative-binomial regression to analyze the association of mean symptom number with viral variant and vaccination status.
Results
Among 2912 participants (median age: 44 years; 81.3% female), PASC symptoms were significantly more frequent after wild-type infection (estimated mean symptom number: 1.12; P < .001; median time since infection: 18.3 months), after Alpha/Delta infection (0.67 symptoms; P < .001; 6.5 months), and after Omicron BA.1 infections (0.52 symptoms; P = .005; 3.1 months) versus uninfected controls (0.39 symptoms). After Omicron BA.1 infection, the estimated mean symptom number was 0.36 for unvaccinated individuals versus 0.71 with 1–2 vaccinations (P = .028) and 0.49 with ≥3 prior vaccinations (P = .30). Adjusting for confounders, only wild-type (adjusted rate ratio [aRR]: 2.81; 95% confidence interval [CI]: 2.08–3.83) and Alpha/Delta infections (aRR: 1.93; 95% CI: 1.10–3.46) were significantly associated with the outcome.
Conclusions
Previous infection with pre-Omicron variants was the strongest risk factor for PASC symptoms among our HCWs. Vaccination before Omicron BA.1 infection was not associated with a clear protective effect against PASC symptoms in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St. Gallen, Switzerland.
- Department of Infectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland.
- Division of Infectious Diseases, Cantonal Hospital of Grisons, Chur, Switzerland.
- Ambulatory Services, Psychiatry Services of the Canton of St. Gallen (South), St. Gallen, Switzerland.
- Ambulatory Services, Psychiatry Services of the Canton of St. Gallen (North), St. Gallen, Switzerland.
- Department of Psychiatry, Clienia Littenheid, Littenheid, Switzerland.
ORCID-Profile: Philipp Kohler
Förderung
- Swiss National Sciences Foundation
Zitieren
APA
Kahlert, C. R., Strahm, C., Güsewell, S., Cusini, A., Brucher, A., Goppel, S., Möller, E., Möller, J. C., Ortner, M., Ruetti, M., Stocker, R., Vuichard-Gysin, D., Besold, U., McGeer, A., Risch, L., Friedl, A., Schlegel, M., Vernazza, P., Kuster, S. P., …, & SURPRISE (SURveillance of infectious diseases among health PRofessionals In SwitzErland) Study Group (2023). Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study. Clinical Infectious Diseases, 77(2), 194-202. https://doi.org/10.1093/cid/ciad143
Vancouver
Kahlert CR, Strahm C, Güsewell S, Cusini A, Brucher A, Goppel S, et al. Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study. Clinical Infectious Diseases. 2023;77(2):194-202. doi:10.1093/cid/ciad143
BibTeX
@article{Kahlert2023,
author = {Kahlert, Christian R and Strahm, Carol and Güsewell, Sabine and Cusini, Alexia and Brucher, Angela and Goppel, Stephan and Möller, Elisabeth and Möller, J Carsten and Ortner, Manuela and Ruetti, Markus and Stocker, Reto and Vuichard-Gysin, Danielle and Besold, Ulrike and McGeer, Allison and Risch, Lorenz and Friedl, Andrée and Schlegel, Matthias and Vernazza, Pietro and Kuster, Stefan P and Kohler, Philipp and SURPRISE (SURveillance of infectious diseases among health PRofessionals In SwitzErland) Study Group, SURPRISE (SURveillance of infectious diseases among health PRofessionals In SwitzErland) Study Group},
title = {Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {77},
number = {2},
pages = {194--202},
doi = {10.1093/cid/ciad143}
}
EUVIMED